Utilizing Predictions of Early Prostate-Specific Antigen Selection for Adjuvant Systemic Therapy Trials

Journal of Clinical Oncology

18, 3240-3246

DOI: 10.1200/jco.2000.18.18.3240

Citation Report

#	Article	IF	Citations
1	The Prostate Journal Database. Prostate Journal, 2001, 3, 131-135.	0.2	0
2	Determinants of Prostate Cancerâ€“Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2002, 20, 4567-4573.	1.6	244
3	Diagnostic accuracy of prostate needle biopsy. Current Urology Reports, 2002, 3, 215-221.	2.2	5
4	The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century. Critical Reviews in Oncology/Hematology, 2002, 42, 179-188.	4.4	5
5	Variations Among Individual Surgeons in the Rate of Positive Surgical Margins in Radical Prostatectomy Specimens. Journal of Urology, 2003, 170, 2292-2295.	0.4	311
6	Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy. Journal of the National Cancer Institute, 2003, 95, 1376-1383.	6.3	475
7	The rationale for adjuvant chemotherapy for high-risk prostate cancer. Current Opinion in Urology, 2003, 13, 123-131.	1.8	2
8	Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy. Cancer, 2004, 101, 96-105.	4.1	49
9	PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPY. Journal of Urology, 2004, 172, S42-6; discussion S46-7.	0.4	125
10	Adjuvant Therapy in High Risk Prostate Cancer:. European Urology Supplements, 2004, 3, 43-50.	0.1	0
11	Positive Surgical Margins and Accessory Pudendal Artery Preservation During Laparoscopic Radical Prostatectomy. European Urology, 2005, 48, 786-792.	1.9	32
12	Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. Prostate Cancer and Prostatic Diseases, 2005, 8, 353-358.	3.9	12
13	Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy. Journal of Clinical Oncology, 2005, 23, 8192-8197.	1.6	60
14	Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 4037-4043.	7.0	198
15	QUALITY IMPROVEMENT IN LAPAROSCOPIC RADICAL PROSTATECTOMY FOR pT2 PROSTATE CANCER: IMPACT OF VIDEO DOCUMENTATION REVIEW ON POSITIVE SURGICAL MARGIN. Journal of Urology, 2005, 173, 765-768.	0.4	59
16	Guidelines for primary radiotherapy of patients with prostate cancer. Radiotherapy and Oncology, 2006, 79, 259-269.	0.6	139
17	Nomograms for prostate cancer. BJU International, 2006, 98, 39-46.	2.5	58
18	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU International, 2006, 98, 1204-1209.	2.5	62

#	Article	IF	Citations
19	Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 395-402.	0.8	36
20	Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. Journal of the National Cancer Institute, 2006, 98, 715-717.	6.3	561
21	Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. Clinical Cancer Research, 2007, 13, 5361-5367.	7.0	82
22	Surgical margin status of open versus laparoscopic radical prostatectomy specimens. International Journal of Urology, 2008, 15, 704-707.	1.0	26
23	Tumor Length in Prostate Cancer. American Journal of Clinical Pathology, 2008, 130, 77-82.	0.7	14
24	Prognostic Significance of Surgical Margin Status after Laparoscopic Radical Prostatectomy: Early Experience in a Single Institution in Japan. Current Urology, 2008, 2, 67-72.	0.6	0
25	Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU International, 2009, 104, 315-320.	2.5	33
26	Predicting Postâ€“External Beam Radiation Therapy PSA Relapse of Prostate Cancer Using Pretreatment MRI. International Journal of Radiation Oncology Biology Physics, 2010, 78, 743-750.	0.8	36
27	Deletions of the Androgen-MetabolizingUGT2BGenes Have an Effect on Circulating Steroid Levels and Biochemical Recurrence after Radical Prostatectomy in Localized Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1550-E1557.	3.6	54
28	Synergistic Effects of the Green Tea Extract Epigallocatechin-3-gallate and Taxane in Eradication of Malignant Human Prostate Tumors. Translational Oncology, 2011, 4, 147-156.	3.7	77
29	Prognostic Factors for Failure after Prostatectomy. Journal of Cancer, 2011, 2, 1-19.	2.5	48
30	SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy. European Urology, 2011, 60, 1226-1234.	1.9	41
31	The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy. European Urology, 2012, 62, 88-96.	1.9	33
32	Positive margins after radical prostatectomy: Implications for failure and role of adjuvant treatment. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 531-541.	1.6	17
33	Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Canadian Urological Association Journal, 2013, 4, 13.	0.6	0
34	Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression. BMC Medical Genetics, 2014, 15, 143.	2.1	20
35	Prostate Cancer: Role of Pretreatment Multiparametric 3-T MRI in Predicting Biochemical Recurrence After Radical Prostatectomy. American Journal of Roentgenology, 2014, 202, W459-W465.	2.2	53
36	Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 331.e1-331.e7.	1.6	6

#	Article	IF	Citations
37	Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. Scandinavian Journal of Urology, 2016, 50, 255-259.	1.0	6
38	Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. Prostate Cancer and Prostatic Diseases, 2016, 19, 28-34.	3.9	13
39	Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy. Prostate, 2019, 79, 1793-1804.	2.3	15
41	Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management:evidentiary base. Canadian Urological Association Journal, 2010, 4, 13-25.	0.6	34
42	Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. Reviews in Urology, 2002, 4, 141-6.	0.9	0
43	Prognostic factors for failure after prostatectomy. Journal of Cancer, 2010, 2, 1-19.	2.5	24
44	Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6. International Journal of Clinical and Experimental Pathology, 2012, 5, 496-502.	0.5	7